CDT Equity Inc (nasdaq:CDT) Share Price

Company Profile

Business description
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company’s current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor, and renal transplant rejection. The Company’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Contact
4581 Tamiami Trail North
Suite 200
NaplesFL34103
USA
T: +1 646 491-9132
https://www.conduitpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6

Recommended

The stocks of these high-quality growth companies look undervalued today.

Margaret Giles | 21 September 2025

Underlying secular growth stronger than we thought.

Roy Van Keulen | 21 September 2025

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,102.10	11.70	0.13%
CAC 40	7,801.17	52.42	-0.67%
DAX 40	23,487.59	151.82	-0.64%
Dow JONES (US)	46,315.27	172.85	0.37%
FTSE 100	9,199.03	17.64	-0.19%
HKSE	26,281.15	263.95	-0.99%
NASDAQ	22,631.48	160.75	0.72%
Nikkei 225	45,493.66	447.85	0.99%
NZX 50 Index	13,141.54	90.12	-0.68%
S&P 500	6,664.36	32.40	0.49%
S&P/ASX 200	8,810.90	11.40	0.13%
SSE Composite Index	3,828.58	8.49	0.22%